BACKGROUND: Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The effects of add-on sotatercept in patients with advanced pulmonary arterial hypertension and a high risk of death are unclear. METHODS: In this phase 3 trial, we randomly assigned patients with pulmonary arterial hypertension (WHO functional class III or IV) and a high 1-year risk of death (Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management Lite 2 risk score,
- Humbert, M.
- McLaughlin, V. V.
- Badesch, D. B.
- Ghofrani, H. A.
- Gibbs, J. S. R.
- Gomberg-Maitland, M.
- Preston, I. R.
- Souza, R.
- Waxman, A. B.
- Moles, V. M.
- Savale, L.
- Vizza, C. D.
- Rosenkranz, S.
- Shi, Y.
- Miller, B.
- Mackenzie, H. S.
- Kim, S. S.
- Loureiro, M. J.
- Patel, M. J.
- Koglin, J.
- Cornell, A. G.
- Hoeper, M. M.
